Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 23942936)

1.

Screening intervention to identify eligible patients and improve accrual to phase II-IV oncology clinical trials.

Chen L, Grant J, Cheung WY, Kennecke HF.

J Oncol Pract. 2013 Jul;9(4):e174-81. doi: 10.1200/JOP.2012.000763. Epub 2013 Mar 5.

2.

Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials.

Carlisle B, Kimmelman J, Ramsay T, MacKinnon N.

Clin Trials. 2015 Feb;12(1):77-83. doi: 10.1177/1740774514558307. Epub 2014 Dec 4.

PMID:
25475878
3.

Improving clinical trial accrual through a novel feedback approach: Lessons learned from a single disease site group.

D'Alimonte L, Deabreu A, Marquez A, Mamedov A, Loblaw A.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):70-3. doi: 10.1016/j.prro.2014.05.009. Epub 2014 Jul 3.

PMID:
25413410
4.

Bayesian modeling and prediction of accrual in multi-regional clinical trials.

Deng Y, Zhang X, Long Q.

Stat Methods Med Res. 2014 Nov 3. pii: 0962280214557581. [Epub ahead of print]

PMID:
25367100
5.

Improving clinical trial accrual by streamlining the referral process.

Afrin LB, Oates JC, Kamen DL.

Int J Med Inform. 2015 Jan;84(1):15-23. doi: 10.1016/j.ijmedinf.2014.09.001. Epub 2014 Sep 16.

PMID:
25256066
6.

Struggles with clinical translation of immune intervention trials.

Skyler JS.

Diabetes Care. 2014 May;37(5):1173-5. doi: 10.2337/dc13-2878. No abstract available.

PMID:
24757221
7.

Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective.

Vanhoff D, Hesser T, Kelly KP, Freyer D, Stork S, Sung L.

BMC Med Res Methodol. 2013 Dec 31;13:154. doi: 10.1186/1471-2288-13-154.

8.
9.

[The good assessment criteria in oncology is not still the one we think].

Bastide C.

Prog Urol. 2013 Nov;23(15):1224. doi: 10.1016/j.purol.2013.08.326. Epub 2013 Oct 7. French. No abstract available.

PMID:
24183080
10.

Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.

Somkin CP, Ackerson L, Husson G, Gomez V, Kolevska T, Goldstein D, Fehrenbacher L.

J Oncol Pract. 2013 Nov;9(6):e275-83. doi: 10.1200/JOP.2013.001120. Epub 2013 Oct 22.

11.

Perceptions of participation in a phase I, II, or III clinical trial among African American patients with cancer: what do refusers say?

Brown RF, Cadet DL, Houlihan RH, Thomson MD, Pratt EC, Sullivan A, Siminoff LA.

J Oncol Pract. 2013 Nov;9(6):287-93. doi: 10.1200/JOP.2013.001039. Epub 2013 Oct 15.

12.

Design-phase prediction of potential cancer clinical trial accrual success using a research data mart.

London JW, Balestrucci L, Chatterjee D, Zhan T.

J Am Med Inform Assoc. 2013 Dec;20(e2):e260-6. doi: 10.1136/amiajnl-2013-001846. Epub 2013 Jul 14.

13.

The bottleneck effect in lung cancer clinical trials.

Gonzalez LE, Sutton SK, Pratt C, Gilbertson M, Antonia S, Quinn GP.

J Cancer Educ. 2013 Sep;28(3):488-93. doi: 10.1007/s13187-013-0491-z.

PMID:
23733149
14.

Communication skills training for healthcare professionals working with people who have cancer.

Moore PM, Rivera Mercado S, Grez Artigues M, Lawrie TA.

Cochrane Database Syst Rev. 2013 Mar 28;3:CD003751. doi: 10.1002/14651858.CD003751.pub3. Review.

PMID:
23543521
15.

Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center experience.

Swain-Cabriales S, Bourdeanu L, Niland J, Stiller T, Somlo G.

Appl Nurs Res. 2013 Aug;26(3):133-5. doi: 10.1016/j.apnr.2013.01.003. Epub 2013 Mar 13.

16.

Clinical trial discussion, referral, and recruitment: physician, patient, and system factors.

Kaplan CP, NĂ¡poles AM, Dohan D, Shelley Hwang E, Melisko M, Nickleach D, Quinn JA, Haas J.

Cancer Causes Control. 2013 May;24(5):979-88. doi: 10.1007/s10552-013-0173-5. Epub 2013 Feb 19.

PMID:
23420328
17.

Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.

Dew A, Khan S, Babinski C, Michel N, Heffernan M, Stephan S, Jordan N, Jovanovic B, Carney P, Bergan R.

Clin Trials. 2013 Apr;10(2):292-9. doi: 10.1177/1740774512471452. Epub 2013 Jan 15.

PMID:
23321266
20.

Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.

Filion M, Forget G, Brochu O, Provencher L, Desbiens C, Doyle C, Poirier B, DuRocher M, Camden S, Lemieux J.

Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453.

PMID:
23060323
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk